Skip to main content

Advertisement

Log in

Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Anti-Saccharomyces cerevisiae antibodies (ASCA) had been known to be specific for Crohn’s disease but it has been found in many other autoimmune diseases like systemic lupus erythematosus (SLE). Furthermore, cross-reactive epitopes on β2-glycoprotein I (β2GPI) and Saccharomyces cerevisiae were found in SLE patients. The aims of this study were to evaluate the frequency of ASCA in patients with SLE and to compare it with that of anti-β2GPI antibodies (aβ2GPI). Sera of 116 patients with SLE were analyzed in this retrospective study. All patients fulfilled at least 4 criteria of the 1997 American College of Rheumatology updated criteria for the classification of SLE. Sera of 160 blood donors were included as normal controls. ASCA IgA and IgG and aβ2GPI antibodies were determined by enzyme-linked immunosorbent assays. The frequency of ASCA (IgG and/or IgA) was significantly higher in SLE patients than in control group (31.9 vs. 3.7 %, p < 10−6). ASCA IgG and ASCA IgA were more frequent in SLE patients than in control group (29.3 vs. 3.1 %, p < 10−6 and 12.1 vs. 0.6 %, p = 10−4, respectively). The mean level of ASCA IgG was higher than that of ASCA IgA (9.5 vs. 6.4 U/ml) but the difference was not statistically significant. The frequencies of aβ2GPI (IgG and/or IgA) and aβ2GPI IgA were significantly higher than those of ASCA (IgG and/or IgA) and ASCA IgA (54.3 vs. 31.9 %, p = 5 × 10−4 and 50.9 vs. 12.1 %, p < 10−6, respectively). Increased ASCA IgG was observed in patients with SLE, suggesting a role of environmental stimuli in its pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788–791

    Article  PubMed  CAS  Google Scholar 

  2. Damoiseaux JG, Bouten B, Linders AM, Austen J, Roozendaal C, Russel MG, Forget PP, Tervaert JW (2002) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol 22:281–288

    Article  PubMed  CAS  Google Scholar 

  3. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y (2005) Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54:1232–1236

    Article  PubMed  CAS  Google Scholar 

  4. Krause I, Monselise Y, Milo G, Weinberger A (2002) Anti-Saccharomyces cerevisiae antibodies–a novel serologic marker for Behcet’s disease. Clin Exp Rheumatol 20:S21–S24

    PubMed  CAS  Google Scholar 

  5. Riente L, Chimenti D, Pratesi F, Delle Sedie A, Tommasi S, Tommasi C, Bombardieri S, Migliorini P (2004) Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 31:920–924

    PubMed  CAS  Google Scholar 

  6. Mallant-Hent RCh, Mary B, von Blomberg E, Yüksel Z, Wahab PJ, Gundy C, Meyer GA, Mulder CJ (2006) Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur J Gastroenterol Hepatol 18:75–78

    Article  PubMed  CAS  Google Scholar 

  7. Toumi D, Mankaï A, Belhadj R, Ghedira-Besbes L, Jeddi M, Ghedira I (2007) Anti-Saccharomyces cerevisiae antibodies in coeliac disease. Scand J Gastroenterol 42:821–826

    Article  PubMed  CAS  Google Scholar 

  8. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM (2007) Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosis. Dig Dis Sci 52:33–39

    Article  PubMed  Google Scholar 

  9. Sakly W, Jeddi M, Ghedira I (2008) Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 53:1983–1987

    Article  PubMed  CAS  Google Scholar 

  10. Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R, Gionchetti P, Campieri M, Bianchi FB (2003) Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 132:473–476

    Article  PubMed  CAS  Google Scholar 

  11. Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R (2009) Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol Dietol 55:37–40

    PubMed  CAS  Google Scholar 

  12. Sakly W, Mankaï A, Sakly N, Thabet Y, Achour A, Ghedira-Besbes L, Jeddi M, Ghedira I (2010) Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes. Endocr Pathol 21:108–114

    Article  PubMed  CAS  Google Scholar 

  13. Yazıcı D, Aydın SZ, Yavuz D, Tarçın O, Deyneli O, Direskeneli H, Akalın S (2010) Anti-saccharomyces cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease. Endocrine 38:194–198

    Article  PubMed  Google Scholar 

  14. Dai H, Li Z, Zhang Y, Lv P, Gao XM (2009) Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 18:1087–1090

    Article  PubMed  CAS  Google Scholar 

  15. Krause I, Blank M, Cervera R, Font J, Matthias T, Pfeiffer S, Wies I, Fraser A, Shoenfeld Y (2007) Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann NY Acad Sci 1108:481–488

    Article  PubMed  CAS  Google Scholar 

  16. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  17. Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:A299–A304

    Article  PubMed  Google Scholar 

  18. Vaile JH, Meddings JB, Yacyshyn BR, Russell AS, Maksymowych WP (1999) Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol 26:128–135

    PubMed  CAS  Google Scholar 

  19. Fresko I, Hamuryudan V, Demir M, Hizli N, Sayman H, Melikoğlu M, Tunç R, Yurdakul S, Yazici H (2001) Intestinal permeability in Behçet’s syndrome. Ann Rheum Dis 60:65–66

    Article  PubMed  CAS  Google Scholar 

  20. D’Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, Vettorato MG, Sturniolo GC (2006) Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn’s disease. Aliment Pharmacol Ther 23:1455–1461

    Article  PubMed  Google Scholar 

  21. Wang SJ, Kao CH, Chen DU, Lan JL (1992) Intestinal permeability test in systemic lupus erythematosus. Chung Hua I Hsueh Tsa Chic (Taipei) 49:29–33

    CAS  Google Scholar 

  22. Sultan SM, Ioannou Y, Isenberg DA (1999) A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 38:917–932

    Article  CAS  Google Scholar 

  23. John LJ, Fromm M, Schulzke JD (2011) Epithelial barriers in intestinal inflammation. Antioxid Redox Signal 15:1255–1270

    Article  PubMed  CAS  Google Scholar 

  24. Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, Mallet JM, Colombel JF, Poulain D (2006) Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology 130:1764–1775

    Article  PubMed  CAS  Google Scholar 

  25. Khalifa M, Kaabia N, Bahri F, Ben Jazia E, Bouajina E, Letaief AO (2007) Infection in systemic lupus erythematosus. Med Mal Infect 37:792–795

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study is supported by Unité de recherche: Auto-immunité et Allergie (03/UR/07-02), Faculté de Pharmacie de Monastir, Tunisia.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Amani Mankaï.

Additional information

Amani Mankaï and Wahiba Sakly contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mankaï, A., Sakly, W., Thabet, Y. et al. Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus. Rheumatol Int 33, 665–669 (2013). https://doi.org/10.1007/s00296-012-2431-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2431-3

Keywords

Navigation